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The utility of ETV1, ETV4 and ETV5 RNA in-situ hybridization in the diagnosis of CIC–DUX
sarcomas
Aims: A recently characterized group of undifferenti-
ated small round cell sarcomas harbours fusions of
the genes CIC and DUX4. Studies report a distinctive
gene expression profile for these sarcomas, including
expression of E26 transformation-specific (ETS) family
proto-oncogenic transcription factors ETV1, ETV4
and ETV5. To test the utility of an ancillary diagnos-
tic technique for these tumours, we evaluated chro-
mogenic RNA in-situ hybridization assays for ETV1,
ETV4 and ETV5 as diagnostic adjuncts for this
emerging group of highly malignant sarcomas.
Methods and results: We tested six confirmed CIC–
DUX4 sarcomas and 105 lesions in the differential,
including 48 Ewing sarcomas for expression of ETV1,
ETV4 and ETV5, scoring expression utilizing a previously
validated scale. ETV1 and ETV4 were positive in five of
six cases, while ETV5 was positive in six of six. No Ewing
sarcoma or other sarcoma tested showed coexpression of
these transcripts, while one ETV1/ETV4/ETV5 triple
positive previously unclassified round cell sarcoma was
identified as harbouring a CIC rearrangement by break-
apart fluorescence in-situ hybridization (FISH).
Conclusion: We identified overexpression of ETV1,
ETV4 and ETV5 transcripts in situ in CIC–DUX4 sar-
comas using a robust assay in routine archival sec-
tions. One previously unclassified round cell sarcoma
showed ETV1/4/5 positivity, and was proved to har-
bour a CIC rearrangement by break-apart FISH. The
sensitivity and specificity observed with our in-situ
hybridization assay implies potential utility as an
ancillary diagnostic technique, particularly when
faced with limited biopsy samples.
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Introduction
There has been an exponential increase in the identifi-
cation of recurrent and/or pathognomonic gene
fusions in a rapidly expanding group of mesenchymal
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lesions of varying biological potential.1 This is particu-
larly true with regard to small round cell sarcomas,
where an increasing spectrum of EWSR1 rearrange-
ment-negative small round cell sarcomas have been
recognized,2 including an intriguing group of sarcomas
harbouring fusions of Capicua transcriptional repressor
(CIC) on chromosome 19 and either, most frequently,
the gene double homeobox 4 (DUX4) on chromosome 4
or, less frequently, the highly related gene double home-
obox 4-like (DUX4L) on chromosome 10. Our experi-
ence3,4 and that of others5,6 with this group of
sarcomas suggests that they are most commonly soft
tissue-based tumours arising across a wide age range,
but predominantly among young adults. They demon-
strate a degree of atypia and pleomorphism that is
beyond that of classic Ewing sarcoma, with higher-
grade nuclear features, vesicular chromatin and more
prominent nucleoli. These tumours also show patchy,
clear cell foci and distinctive areas of myxoid change.
Complicating their recognition, especially in limited
core biopsies, these sarcomas show highly prevalent
expression of the ETS-family proto-oncogenic tran-
scription factors, FLI1 and ERG, similar to Ewing sar-
coma, but with more variable and less distinctive
membranous CD99 expression.4,6 Underscoring the
importance of their recognition, cumulative evidence
suggests that these tumours are more aggressive than
Ewing sarcoma, an assumption supported by a recent
large Japanese-based cohort of 20 cases.7
It is the opinion of the authors that the shared
expression of ETS-family proto-oncogenic transcription
factors seen in Ewing sarcoma and CIC–DUX sarcomas
represents not only a diagnostic challenge, but also a
potential avenue for diagnosis. While, in Ewing sarco-
mas, expression of FLI1 and ERG is related to transloca-
tion and oncogenic fusion of EWSR1 to FLI1 or (less
frequently) ERG, in experimental systems, expression
of the CIC–DUX4 fusion oncoprotein appears sufficient
to induce8 expression of multiple other members of the
PEA3 subfamily of the ETS-family of transcription fac-
tors. While we have seen coexpression of both FLI1
and ERG in these tumours by immunohistochemistry
(IHC),4 comprehensive transcriptional profiling by
another group6 has confirmed up-regulation of ETS-
family transcription factors, including ETV1, ETV4 and
ETV5, as part of a core gene signature of CIC–DUX4
sarcomas that is distinctive from Ewing sarcomas.
Based on experience assaying for ETS-family gene
fusions9 in archival sections of prostatic adenocarci-
noma, where the high degree of homology between
ETV1, ETV4 and ETV5 prevented our distinguishing
expression of each of these three reliably by IHC, we
have recently developed and validated a facile,
exquisitely paralogue-specific chromogenic RNA in-situ
hybridization strategy for their detection from standard
archival sections.10 This technique results in reliable,
quantitative detection of the specific RNA species as a
punctate cytoplasmic dot of red chromogen. Herein,
we evaluated the potential utility of this technology for
distinguishing CIC–DUX4 sarcomas from Ewing sar-
coma and a subset of other round cell sarcomas in the
differential.
Materials and methods
C O H O R T S T E S T E D
A retrospective cohort of archival tissues, consisting
of whole sections and tissue microarrays, was assem-
bled for testing. This included a tissue microarray
(TMA) of Ewing sarcomas (n = 37) and CIC–DUX4
sarcomas (n = 6, cases 1–4 and 7–8, as reported
previously4); a TMA of assorted small round cell
sarcomas including additional Ewing sarcomas,
n = 11; high-grade myxoid liposarcomas with round
cell morphology (n = 8); rhabdomyosarcomas
(n = 10, nine alveolar, one adult spindle cell); and a
TMA of high-grade synovial sarcomas (n = 38). Addi-
tional whole sections of each of the six CIC–DUX4
sarcomas were also used for evaluation of the vari-
ability of staining across the sections.
C H R O M O G E N I C R N A I N - S I T U H Y B R I D I Z A T I O N
( I S H )
Our chromogenic RNA in-situ hybridization protocol
for detection of ETV1, ETV4 and ETV5 transcripts,
including its validation with respect to exquisite speci-
ficity to ETV1, ETV4 or ETV5 expression (proved by
comparison to prostate carcinomas proved to harbour
ETV1, ETV4 or ETV5 rearrangements) has been
detailed previously.10 We used RNA scope probes,
designed by Advanced Cell Diagnostics (Hayward,
CA, USA) for ETV1 (transcript region 998–2031,
#311411), ETV4 (transcript region 431–1891,
#491521) and ETV5 (region 2638–3839, #590371)
and POLR2A (positive control). In brief, archival sec-
tions of TMAs and whole formalin-fixed paraffin-
embedded (FFPE) tissue sections were baked at 60°C
for 1 h, deparaffinized in xylene twice for 15 min,
washed in 100% ethanol twice for 3 min and air-
dried for 5 min. Slides were treated with pretreatment
1, 2 and 3 buffers as described previously,10 rinsed in
deionized water and then incubated with the ETV1,
4, 5 or control probes for 2 h at 40°C in a humidity
chamber. Slides were then treated with Amp
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solutions 1–6, before chromogen was developed by
adding a solution of 1:60 fast red B:fast red A for
10 min, washes and counterstaining in 50% haema-
toxylin, 0.01% ammonium hydroxide wash, dehydra-
tion in ethanol and xylene and mounting in Cytoseal
XYL (ThermoScientific, Waltham, MA, USA; #8312-
4) for routine microscopy.
E V A L U A T I O N O F I S H S T A I N I N G
ETV1, ETV4 and ETV5 expression, present as distinct,
punctate cytoplasmic dots, was evaluated using our
scoring system for quantitative expression differences,
which has been validated previously analytically10
and clinically.11 Sections were evaluated using a 920
objective based on the number of punctate dots/cell.
As reported previously, staining level was assessed as
one of five levels, from 0 to 4. Level 0 was defined as
no staining or fewer than 1 dot/cell; level 1 was
defined as 1–3 dots/cell in >5% of the tumour; level
2 was defined as 4–10 dots/cell with minimal cluster-
ing apparent in >5% of the tumour; level 3 was
defined as more than 10 dots/cell with dot clustering
apparent in <10% of cells and level 4 was defined as
more than 10 dots/cell with >10% of the cells with
clusters of dots. As validated previously, scores of 0
or 1+ were considered negative, while scores of 2–4
were considered positive. Each sample was scored
based on the highest intensity observed.
Results
Overall, CIC–DUX4 sarcomas demonstrated positive
staining for ETV1 in five of six cases, for ETV4 in five
of six cases and for ETV5 in six of six cases (one case
was only positive for ETV5). In many cases the stain-
ing was strong and evident at low power (Figure 1A–
F). Overall, ETV4 and ETV5 expression scores tended
to be greater than that of ETV1 (P = 0.0091, Fried-
man’s test). Of 48 well-characterized, classic and
extraskeletal Ewing sarcomas, no case demonstrated
coincident aberrant positive staining for ETV1, ETV4
and ETV5; two Ewing cases showed positive staining
for ETV4 only (2+) or ETV5 only (2+). No staining in
the positive range was seen in 36 synovial sarcomas,
eight myxoid liposarcomas or 11 rhabdomyosarco-
mas. One EWSR1 rearrangement-negative unclassi-
fied round cell sarcoma included in the TMA
evaluable in the ISH slides demonstrated ETV1/ETV4/
ETV5 triple positivity; based on this suggestive find-
ing, we performed CIC break-apart FISH,3 confirming
a rearrangement at the CIC locus (Figure 2A–F).
Discussion
The differential diagnosis of malignancies with small
round cell morphology, especially small round cell sar-
comas, is complicated by several factors in tandem.
These include a rapid proliferation of newly appreci-
ated, clinically relevant entities and variants2 that
must be recognized increasingly in smaller samples
from minimally invasive diagnostic image-guided sam-
pling,12 performed to guide increasing use of neoadju-
vant therapeutic regimens.13 Such factors have driven
increasing use of immunohistochemical biomarkers
for sarcoma diagnosis14 and triage for definitive
molecular testing based on tiny tissue samples. In
Ewing sarcoma, for instance, several markers with
varying sensitivity and specificity have been proposed
with varying success, including most recently NKX2-
2,15 as well as FLI1,16 a marker also detected at
higher concentrations by monoclonal antibodies to the
highly homologous ETS-family member, ERG.17 At
lower concentrations, ERG immunostain may detect
only the small subset of Ewing sarcomas harbouring
ERG rearrangements,18 emphasizing the challenges in
this area. In any case, both markers seem positive in
CIC–DUX4 sarcomas in this differential.4,6 Indeed, the
challenges of IHC validation of transcription factors in
the closely related ETS family of transcription factors
were the reason for our previous efforts to develop and
validate this RNA in-situ hybridization platform for use
in the detection of overexpression of ETV1, ETV4 and
ETV5 driven by oncogenic gene fusions of these genes
with androgen-responsive genes in subsets of prostatic
adenocarcinomas.10
In this study we observed a sensitivity (83%, 83%
and 100% for ETV1, ETV4 and ETV5, respectively)
and specificity (100%) for CIC–DUX4 sarcomas,
which compares favourably with markers currently
in use for this and other differential diagnoses in soft
tissue pathology. One EWSR1 rearrangement-nega-
tive undifferentiated soft tissue sarcoma in the TMA,
arising in the groin of a 31-year-old patient of Afri-
can descent who developed pulmonary and epidural
metastases and died of disease, showed triple positiv-
ity (3+ each for ETV1/4/5). Rearrangement was
detected at the CIC locus by break-apart FISH, sup-
porting the potential utility for this assay to identify
cases prospectively, including in tiny samples of the
size of a TMA core.
Certainly, these findings suffer from limitations of
sample size, retrospective design and limitation to the
CIC–DUX4 sarcomas tested (we were unable to test
any CIC-rearranged sarcomas with the CIC–DUX4L
fusion4,6 or recently reported CIC–FOXO4
© 2016 John Wiley & Sons Ltd, Histopathology, 70, 657–663.
ETV1/4/5 expression in CIC–DUX sarcomas 659
fusions,19,20 while the presumptive CIC fusion partner
in the positive case we discovered remains unknown,
as do many cases tested by FISH alone7). However,
we note that these remain rare tumours, with little in
the way of diagnostic adjuncts to support their identi-
fication from the significant subset of round cell sar-
comas that remain unclassified.
Previously, we have reported promising findings for
use of a panel of IHC markers including ETV4,21 and
others have reported recently utility for ETV4 and
WT1 as IHC markers for CIC-rearranged sarco-
mas.22,23 Notably, we have not tested any BCOR–
CCNB3 sarcomas,24 although we note that ETV4 IHC
has been negative in nine cases tested in two recent
A B C
D E F
G H I
ETV1 ETV4 ETV5
ETV1, 1+ ETV4, 2+ ETV5, 4+
Figure 1. CIC–DUX4 sarcomas show prominent nodular growth and a primitive round cell morphology (A) with frequently observed myxoid
change (B) and high-grade nuclear cytology (C). As seen in in-situ hybridization slides performed on consecutive sections to that of (A), even
at low power inspection, positive staining for the indicated ETS-family member transcript was identified readily (D–F). A staining pattern
ranging from only punctate dots (G; 1+, considered negative) to positive staining at 2+ (H) up to 4+ (I) was observed.
© 2016 John Wiley & Sons Ltd, Histopathology, 70, 657–663.
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reports.22,23 Despite the potential utility, the ETV4
IHC findings remain of unproved technical specificity
to ETV4, as opposed to the other highly homologous
ETS-family members (FLI1, ERG, ETV1, ETV5, etc.)
overexpressed in CIC–DUX sarcomas,6 the initial con-
cern of which led to our use of RNA-based specific
detection. Overall, at present WT1 (N-terminal)
remains the IHC marker that we have used most fre-
quently as a marker for triage of EWSR1 rearrange-
ment-negative undifferentiated soft tissue sarcomas in
the differential with CIC-rearranged sarcoma, which
the published data suggest is quite sensitive but not
necessarily specific.6,22
In fact, our experience with the technical advan-
tages of this RNA ISH system suggest that this tech-
nology might have broad potential for assay
development not only where in-vitro diagnostic-qual-
ity antibodies are unavailable, but where discrimina-
tion among highly homologous proteins based on
specific RNA species is of utility. In this RNA ISH
approach, specificity is conferred not only by the
sequence specificity of probes hybridizing to the target
RNA species, but by use of paired, adjacent ‘ZZ’
probes, hybridization of both of which is required for
amplification and detection.25 While requiring imple-
mentation of a new workflow in advance (compared
to introducing a new IHC marker into existing pro-
cesses), RNA ISH allows rapid, specific implementa-
tion of any transcript as a diagnostic marker,
independent of availability of a robust, specific anti-
body for detection. This particular advantage was
illustrated recently for detection of FGF23 RNA spe-
cies in phosphaturic mesenchymal tumours,26 a simi-
lar scenario without available specific antibodies.
Moreover, the platform is quite amenable for use in
cases where IHC-based detection remains suboptimal,
such as for detection of viral RNA species [e.g.
human papilloma virus (HPV) in head and neck
A B C
D E F
CIC
Figure 2. A previously unclassified (EWSR1 rearrangement negative) round cell sarcoma arising in the soft tissues of the groin of a 31-year-
old male patient was included in the tissue microarray (TMA) studied by the in-situ hybridization assays. Morphologically, it demonstrated
septate, nodular growth of high-grade, undifferentiated primitive round cells with prominent necrosis and discohesion (A). At higher power,
the nuclear pleomorphism and atypia were somewhat more than expected for a classic Ewing sarcoma (B). TMA cores demonstrated positive
(3+) staining for ETV1 (B), ETV4 (C) and ETV5 (D; each inset low power showing proportion positivity), a suspicious finding that we found
to be associated with rearrangement at the CIC locus, proved by break-apart fluorescence in-situ hybridization (F).
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cancer specimens27], such that addition and valida-
tion of markers such as these ETS family members
might be even more facile.
In future, while molecular studies including break-
apart FISH [or reverse transcription–polymerase
chain reaction (RT–PCR)] are currently deemed the
gold diagnostic standard for CIC-rearranged sarco-
mas, and which we continue to use for confirmation
in any case of uncertainty, we note that such studies
often require significant samples of tissue. While, as
used herein, our ETV studies would require three rou-
tine sections, we note that recently reported duplex
or multiplex RNA in-situ hybridizations28 might be
used for specific, simultaneous detection of multiple
ETS-family species in the same tissue section, further
sparing tissue for downstream studies. In the context
of the rapid proliferation of characteristic and even
pathognomonic molecular lesions in mesenchymal
tumours, our observations lend even further support
for the development of RNA in-situ hybridization as a
means for rapid translation of promising markers
from profiling studies into diagnostic use.
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